News of Spark Therapeutics’ breakthrough gene therapy for inherited blindness being priced at $850,000 was the most-read retina-related article on Healio.com/OSN in January.
The company’s licensing agreement with Novartis for the treatment outside of the United States also made the list.
Here are the top five most-read retina articles from January:
1. Price for Spark ’ s gene therapy for blindness set at $850,000
The wholesale acquisition cost of one-time Luxturna treatment for confirmed biallelic RPE65 mutation-associated retinal dystrophy is $425,000 per eye. Read more.
Uncategorized